

For Immediate Release:  
July 1, 2014

**Traverse Biosciences Selected to Present at the 6<sup>th</sup> Annual Animal Health and Investment Forum, to be held August 26, 2014 in Kansas City, Missouri**

**Stony Brook, NY; July 1, 2014:** Traverse Biosciences announced today that it has been selected as one of 15 companies competitively chosen to present at the 6<sup>th</sup> Annual Animal Health Investment Forum, to be held August 26, 2014 at the Kansas City Convention Center in Kansas City, Missouri. The KC Animal Health Investment Forum offers one of the only opportunities in the world for early stage companies in the animal health sector to present their vision and business plan to potential investors and established animal health companies. Thirty companies made application this year, and the 2014 Selection Committee indicated that it was the most qualified group of applicants since inception of the program in 2009.

The members of the 2014 Selection Committee have a long and distinguished track record in the animal health industry. They bring a mixture of entrepreneurial and established company experience and understand the financial aspects of developing and acquiring technologies. Facilitated by Expedite Animal Health, the 2014 Selection Committee members include:

- Bill Anderson, Acting Executive Director, Missouri Technology Corporation
- Stan Baker, Patent Attorney, Husch Blackwell, LLP
- Jeff Boily, President & CEO, Centaur Animal Health
- Dr. Sam Al-Murrani, Chief Executive Officer, Babylon BioConsulting LLC
- Jane Eagleson, Owner, Bleecker Street Consulting
- John Mannhaupt, Vice President, Brakke Consulting, Inc.
- Ronald Meeusen, PhD, Founding Partner, Cultivian Sandbox Food and Ag Funds I & II
- Chris Ragland, CEO, Animalytix, LLC
- Rich Shuler, President & CEO, Shuler Consulting Services
- Tony Simpson, Director of Commercialization, Kansas Bioscience Authority
- Susan Warren, Branch Manager, Patterson Veterinary

Companies selected to present have also been invited to the Homecoming Dinner on Monday, August 25, which will be attended by almost 800 animal health executives. Moreover, Traverse Biosciences has been assigned a "KC Ambassador" to facilitate networking opportunities and introductions to key contacts in the industry who will be attending the event.

Mr. Joseph Scaduto, Founder and CEO of Traverse Biosciences, said, "We are honored to have been selected to present at the KC Animal Health Investment Forum, which will provide Traverse Biosciences a unique opportunity to network with prospective investors and potential strategic partners, as well as regulatory consultants, business advisors, key opinion leaders, and members of the veterinary community."

**About Expedite Animal Health:** Expedite serves the animal health industry by “de-risking” early stage opportunities ranging from specific technologies to complete companies. Expedite analyzes these technologies to identify necessary advances that are needed to arrive at a point at which a more informed decision can be made regarding further investment. For more information, contact Tom Overbay at 913-449-2845 or [toverbay@expediteanimalhealth.com](mailto:toverbay@expediteanimalhealth.com).

**About the KC Animal Health Investment Forum:** The KC Animal Health Investment Forum provides a unique opportunity for venture capital funds, investment firms and animal health companies to hear from emerging companies with the newest technology. The Forum showcases animal health and nutrition companies from throughout the world. Companies presenting at the Forum have raised over \$130 million. Several have also received licensing agreements or distribution contracts. For more information, visit [www.kcanimalhealthforum.com](http://www.kcanimalhealthforum.com).

**About Traverse Biosciences:** Traverse Biosciences is a privately-held emerging bioscience company launched to commercialize a proprietary pipeline of drug candidates to treat inflammatory diseases and age-related conditions affecting humans and companion animals. The company’s lead compound, TRB-N0224, is envisioned as the first FDA-approved, once-daily, edible prescription medication for the prevention of canine periodontal disease. For more information, visit [www.traversebiosciences.com](http://www.traversebiosciences.com).